We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+8.1%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$377M
AUM Growth
-$57.5M
Cap. Flow
-$56.5M
Cap. Flow %
-14.97%
Top 10 Hldgs %
44.25%
Holding
64
New
18
Increased
9
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$17.1M
2
CELG
Celgene Corp
CELG
+$15.2M
3
AKBA icon
Akebia Therapeutics
AKBA
+$9.63M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.36M
5
OMER icon
Omeros
OMER
+$7.86M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$38.6M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$21.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$16.5M
5
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 77.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
26
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.61M 1.49%
+33,333
New +$5.75M
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.39M 1.43%
120,000
+60,000
+100% +$2.47M
AGTC
28
DELISTED
Applied Genetic Technologies Corporation
AGTC
$5.05M 1.34%
+218,600
New +$3.85M
ALKS icon
29
Alkermes
ALKS
$8.39B
$5.03M 1.33%
100,000
-100,000
-50% -$4.61M
RMTI icon
30
Rockwell Medical
RMTI
$28M
$4.8M 1.27%
3,636
– –
ARRY
31
DELISTED
Array Biopharma Inc
ARRY
$4.56M 1.21%
1,000,000
-750,000
-43% -$3.1M
PBYI icon
32
CALL
Puma Biotechnology
PBYI
$402M
$4.5M 1.19%
+5,000
New +$356K
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
$4.49M 1.19%
300,000
-100,000
-25% -$1.58M
NBIX icon
34
Neurocrine Biosciences
NBIX
$18.7B
$4.45M 1.18%
+300,000
New +$4.23M
CBPO
35
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$4.45M 1.18%
+100,000
New +$4.08M
QTNT
36
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.18M 1.11%
+12,500
New +$3.91M
SCTL
37
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4M 1.06%
557,500
– –
CBIO
38
Crescent Biopharma
CBIO
$555M
$3.98M 1.05%
4,723
+29
+0.6% +$28.9K
PTCT icon
39
PTC Therapeutics
PTCT
$6.26B
$3.92M 1.04%
150,000
-400,000
-73% -$8.56M
GNVC
40
DELISTED
GenVec, Inc.
GNVC
$3.42M 0.91%
132,930
– –
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$27.4B
$3.16M 0.84%
50,000
– –
ALDR
42
DELISTED
Alder Biopharmaceuticals
ALDR
$3.01M 0.8%
+150,000
New +$2.11M
CLVS
43
DELISTED
Clovis Oncology, Inc.
CLVS
$2.9M 0.77%
70,000
-50,000
-42% -$2.58M
AGEN
44
Agenus
AGEN
$329M
$2.9M 0.77%
45,855
-5,095
-10% -$295K
NGNE icon
45
Neurogene
NGNE
$670M
$2.83M 0.75%
15,000
+2,656
+22% +$512K
DARE icon
46
Dare Bioscience
DARE
$18.6M
$2.61M 0.69%
+3,750
New +$2.89M
ASPX
47
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.23M 0.59%
100,000
– –
KIN
48
DELISTED
Kindred Biosciences, Inc.
KIN
$1.86M 0.49%
+100,000
New +$1.7M
RGLS
49
DELISTED
Regulus Therapeutics
RGLS
$1.61M 0.43%
1,667
– –
AGRX
50
DELISTED
Agile Therapeutics
AGRX
$1.31M 0.35%
+75
New +$1.09M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Cormorant Asset Management held 64 positions worth $377M, down 13% from $435M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $56.5M in Q2 2014, closing 10 positions and reducing 13 holdings. Its most notable exit was MEDIVATION, INC., an estimated $38.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 70% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in QUESTCOR PHARMA INC worth $18.5M.

  • Cormorant Asset Management's largest Q2 2014 buy was QUESTCOR PHARMA INC: 200,000 shares worth $18.5M.
  • Cormorant Asset Management added most to Omeros in Q2 2014, an estimated $7.86M increase.
  • Cormorant Asset Management's biggest Q2 2014 reduction was PTC Therapeutics, cutting an estimated $8.56M.
  • Cormorant Asset Management fully exited MEDIVATION, INC. in Q2 2014, selling an estimated $38.6M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $377M portfolio in Q2 2014.
  • Cormorant Asset Management opened 18 new positions and closed 10 in Q2 2014.
  • Cormorant Asset Management's portfolio value fell 13% quarter-over-quarter to $377M.

Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.